Mast Therapeutics' MST-188 Gets Orphan Drug Status - Quick Facts

(RTTNews) - Mast Therapeutics Inc. (MSTX), Wednesday said its MST-188 for the treatment of acute limb ischemia received orphan drug status from the U.S. Food and Drug Administration or FDA.

As previously announced, the company said it is on track to start a phase 2, clinical proof-of-concept study in acute limb ischemia in early 2014. Provided this study shows that the drug improves 'clot busting' activity of tPA in acute limb ischemia, the company will design a registrational phase 3 study in that orphan disease. Additionally, it will generate data to support development in indications with even larger market opportunities, such as stroke.